World's Best Scientists 2026 revealed!
Jonathan W. Friedberg

Jonathan W. Friedberg

D-Index & Metrics

Medicine

D-Index
87
Citations
35154
World Ranking
13478
National Ranking
6854

Jonathan W. Friedberg publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jonathan W. Friedberg sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 595 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jonathan W. Friedberg D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jonathan W. Friedberg sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jonathan W. Friedberg is affiliated with the University of Rochester in the United States and has contributed extensively to the field of medicine, particularly in oncology and pathology. Their research primarily addresses lymphoma diagnosis and treatment, chronic lymphocytic leukemia, as well as lung cancer and central nervous system lymphoma. Other areas of focus include CAR-T cell therapy, viral-associated cancers, and cancer genomics and diagnostics.

Their work spans several specialized subfields, including pathology and forensic medicine, oncology, genetics, pulmonary and respiratory medicine, and neurology. The volume of publications reflects a concentrated expertise in these areas, with a significant focus on hematologic malignancies and related therapies.

Frequent coauthors include:

  • Brad S. Kahl
  • John P. Leonard
  • Christopher R. Flowers
  • Nancy L. Bartlett
  • Brian K. Link

Jonathan W. Friedberg has published extensively in respected scientific journals. The most frequent publication venues are:

  • Blood
  • Journal of Clinical Oncology
  • Hematological Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances

Selected recent papers that illustrate their research focus are:

  • "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee," 2022, Blood
  • "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma," 2022, New England Journal of Medicine
  • "Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma," 2020, Journal of Clinical Oncology
  • "Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma," 2024, New England Journal of Medicine
  • "Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001," 2020, Journal of Clinical Oncology

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

    Jonathan W. Friedberg;Jeff Sharman;John Sweetenham;Patrick B. Johnston

  • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon

  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

    James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Jonathan W. Friedberg

  • Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors

    Andrea K. Ng;M. V. Patricia Bernardo;Edie Weller;Kendall Backstrand

  • Long-Term Survival and Competing Causes of Death in Patients With Early-Stage Hodgkin’s Disease Treated at Age 50 or Younger

    Andrea K. Ng;M. Patricia Bernardo;Edie Weller;Kendall H. Backstrand

  • Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

    Jonathan W. Friedberg;Philip Cohen;Ling Chen;K. Sue Robinson

  • Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study

    Gary H. Lyman;David C. Dale;Jonathan Friedberg;Jeffrey Crawford

  • Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

    Patrick J. Stiff;Joseph M. Unger;James R. Cook;Louis S. Constine

  • Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

    Jonathan W. Friedberg;Michael D. Taylor;James R. Cerhan;Christopher R. Flowers

  • Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

    Lindsay M. Morton;Susan L. Slager;James R. Cerhan;Sophia S. Wang

  • Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

    Leo I. Gordon;Fangxin Hong;Richard I. Fisher;Nancy L. Bartlett

  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Nancy L. Bartlett;Wyndham H. Wilson;Sin Ho Jung;Eric D. Hsi

  • Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

    Anas Younes;Catherine Thieblemont;Franck Morschhauser;Ian Flinn

  • US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

    Oliver W. Press;Oliver W. Press;Hongli Li;Heiko Schöder;David J. Straus

  • Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516—The Southwest Oncology Group

    Steven H. Bernstein;Joseph M. Unger;Michael LeBlanc;Jonathan Friedberg

  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

    NL Bartlett;D Niedzwiecki;JL Johnson;JW Friedberg

Frequent Co-Authors

Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
John P. Leonard
John P. Leonard Cornell University
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Richard I. Fisher
Richard I. Fisher Fox Chase Cancer Center
Christopher R. Flowers
Christopher R. Flowers The University of Texas MD Anderson Cancer Center
Bruce D. Cheson
Bruce D. Cheson Georgetown University
Louis S. Constine
Louis S. Constine University of Rochester Medical Center
Lisa M. Rimsza
Lisa M. Rimsza Mayo Clinic
Leo I. Gordon
Leo I. Gordon Northwestern University
Oliver W. Press
Oliver W. Press University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA opens various career pathways and related online degrees for aspiring healthcare professionals. If you are interested in patient care but want a flexible application process, you might explore nursing programs without TEAS requirements. These programs remove common testing barriers and make it easier for students to begin nursing studies.

For those seeking leadership roles in healthcare, an accelerated healthcare administration degree can prepare you for management opportunities quickly and conveniently online. Similarly, registered nurses aiming to advance can benefit from seamless pathways such as an ASN to NP (Associate of Science in Nursing to Nurse Practitioner) bridge program. These options enable you to grow your expertise and scope of practice efficiently.

In addition, there is high demand for professionals with an online bachelor's degree in nutrition, supporting patients' health through diet and wellness. Choosing a related degree or career pathway can lead to fulfilling roles beyond traditional medicine and create more options within the growing healthcare sector.

Best Scientists Citing Jonathan W. Friedberg

Trending Scientists